DEST — Destiny Pharma Share News
0.000.00%
Last trade - 00:00Presentation at ESCMID on XF-73 Nasal Gel
Director/PDMR Shareholding
XF-73 prevents bacterial invasion of bloodstream
Treatment of XF-73 Nasal reduces antibiotic use
Exercise of Options and Total Voting Rights
Brief: Destiny Pharma Reports Efficacy Of XF-70 In Fungal Skin Infections
2024 Annual General Meeting and Statement
Destiny Pharma's XF-73 Nasal Awarded MHRA ILAP
Posting of Annual Report and Notice of AGM
Full year results and review of strategic options
Notice of Full Year Results
Brief: Destiny Pharma Says Positive Results From XF-73 Dermal Safety Study
Clinical development update
Brief: Destiny Pharma Evaluates All Options To Achieve Maximum Value For XF-73 Nasal Asset
Year End Business Update
Grant of Share Options
Director/PDMR Shareholding
Director/PDMR Shareholding
Director/PDMR Shareholding